2. Signaling Pathways
  3. GPCR/G Protein
    MAPK/ERK Pathway
  4. Ras

Ras

Ras

Related Products

PDF 2.6 MB

Ras is the name given to a family of related proteins which is ubiquitously expressed in all cell lineages and organs. All Ras protein family members belong to a class of protein called small GTPase, and are involved in transmitting signals within cells. Ras is the prototypical member of the Ras superfamily of proteins, which are all related in 3D structure and regulate diverse cell behaviours. When Ras is 'switched on' by incoming signals, it subsequently switches on other proteins, which ultimately turn on genes involved in cell growth, differentiation and survival. As a result, mutations in ras genes can lead to the production of permanently activated Ras proteins. This can cause unintended and overactive signalling inside the cell, even in the absence of incoming signals. Because these signals result in cell growth and division, overactive Ras signaling can ultimately lead to cancer. The 3 Ras genes in humans (HRAS,KRAS, and NRAS) are the most common oncogenes in human cancer; Ras inhibitors are being studied as a treatment for cancer, and other diseases with Ras overexpression.

Ras Isoform Specific Products:

Ras Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-16111A
    BMS-214662 hydrochloride
    		Inhibitor 98.54%
    BMS-214662 hydrochloride is an inhibitor of farnesyltransferase (Farnesyl Transferase). BMS-214662 hydrochloride can effectively block the localization and function of Ras proteins on the cell membrane by inhibiting the prenylation modification of Ras proteins, thereby exerting anti-tumor activity. The IC50 value of BMS-214662 hydrochloride for H-Ras is 1.3 nM, and for K-Ras it is 8.4 nM. BMS-214662 hydrochloride can be used in the research of tumor diseases related to Ras.
    BMS-214662 hydrochloride
  • HY-12446
    K-Ras(G12C) inhibitor 9
    		Inhibitor ≥98.0%
    K-Ras (G12C) inhibitor 9 is an allosteric inhibitor of the K-Ras (G12C).
    K-Ras(G12C) inhibitor 9
  • HY-15872
    FTI-277
    		Inhibitor
    FTI-277 is an inhibitor of farnesyl transferase (FTase); a highly potent Ras CAAX peptidomimetic which antagonizes both H- and K-Ras oncogenic signaling. FTI-277 can inhibit hepatitis delta virus (HDV) infection.
    FTI-277
  • HY-N10336
    Notoginsenoside R4
    		99.84%
    Notoginsenoside R4 is a ginsenoside that can be isolated from ginseng roots. In the molecular docking results, Notoginsenoside R4 can target STAT3, AKT1, HRAS, VEGFA and CASP3.
    Notoginsenoside R4
  • HY-P10600
    BIMAX2
    		Inhibitor
    BIMAX2 is a high affinity nuclear localization signal (NLS) peptide. BIMAX2 can mimic the activity of the classical nuclear localization signal (cNLS) and competitively bind to importin α, thereby inhibiting the binding of cNLS-cargo proteins to importin α. BIMAX2 can be used to study the role of RBBP4 in regulating nuclear import efficiency and cell senescence.
    BIMAX2
  • HY-135864
    KRAS inhibitor-6
    		Inhibitor
    KRAS inhibitor-6 is a potent KRAS G12C inhibitor, extracted from patent WO2017087528A1, compound A.
    KRAS inhibitor-6
  • HY-135866
    KRAS inhibitor-8
    		Inhibitor
    KRAS inhibitor-8 is a potent KRAS G12C inhibitor, extracted from patent WO2017087528A1, compound C.
    KRAS inhibitor-8
  • HY-135865
    KRAS inhibitor-7
    		Inhibitor
    KRAS inhibitor-7 is a potent KRAS G12C inhibitor, extracted from patent WO2017087528A1, compound B.
    KRAS inhibitor-7
  • HY-132920
    KRAS mutant protein inhibitor 1
    		Inhibitor
    KRAS mutant protein inhibitor 1 is a KRAS mutant protein inhibitor for potential research in cancer.
    KRAS mutant protein inhibitor 1
  • HY-142487
    KRAS G12C inhibitor 32
    		Inhibitor
    KRAS G12C inhibitor 32, an eight membered heterocyclic compound containing N, is a potent KRAS G12C inhibitor.
    KRAS G12C inhibitor 32
  • HY-160866
    (Rac)-D3S-001
    		Control
    (Rac)-D3S-001 is the racemate of D3S-001 (HY-160023).
    (Rac)-D3S-001
  • HY-142458
    KRAS G12C inhibitor 27
    		Inhibitor
    KRAS G12C inhibitor 27 is a KRAS G12C inhibitor with antitumor effects (WO2021109737).
    KRAS G12C inhibitor 27
  • HY-144212
    SOS1-IN-8
    		Inhibitor
    SOS1-IN-8 is a potent SOS1 inhibitor with IC50s of 11.6 and 40.7 nM for SOS1-G12D and SOS1-G12V, respectively (WO2022017339A1, compound 2).
    SOS1-IN-8
  • HY-115880
    KRAS G12D inhibitor 3
    		Inhibitor
    KRAS G12D inhibitor 3 is a KRAS G12D inhibitor with an IC50 of <500 nM. KRAS G12D inhibitor 3 has antitumor effects (WO2022002102A1; compound 146). KRAS G12D inhibitor 3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    KRAS G12D inhibitor 3
  • HY-N2907R
    Atranorin (Standard)
    		Inhibitor
    Atranorin (Standard) is the analytical standard of Atranorin. This product is intended for research and analytical applications. Atranorin is a lichen secondary metabolite. Atranorin inhibits lung cancer cell motility and tumorigenesis by affecting AP-1, Wnt, and STAT signaling and suppressing RhoGTPase activity.
    Atranorin (Standard)
  • HY-153262
    KRASG12C IN-2
    		Inhibitor
    KRASG12C IN-2 (compound 17) is an orally active KRASG12C inhibitor. KRASG12C IN-2 inhibits tumor growth in mice.
    KRASG12C IN-2
  • HY-150927
    G12Si-2
    		Inhibitor
    G12Si-2, an analog of G12Si-1 (HY-150926), is a negative control tool. G12Si-2 is not a covalent inhibitor of the G12S mutant of K-Ras.
    G12Si-2
  • HY-150926
    G12Si-1
    		Inhibitor
    G12Si-1 is a selective K-Ras(G12S) covalent inhibitor, which can inhibit oncogenic signaling of K-Ras(G12S). G12Si-1 shows good ability to covalently engage recombinant K-Ras(G12S) at the mutant serine residue. G12Si-1 can also affect nucleotide cycling of K-Ras by blocking Sos-catalyzed exchange and decreasing the rate of EDTA promoted exchange.
    G12Si-1
  • HY-129189
    RAS GTPase inhibitor 1
    		Inhibitor
    RAS GTPase inhibitor 1 (example 51) is a RAS GTPase inhibitor with anti-tumor activity, extracted from patent WO2018212774A1. RAS GTPase inhibitor 1 (example 51) exhibits an EC50 less than 1 μM for at least one nucleotide exchange and an IC50 less than 1 μM in H727 cells.
    RAS GTPase inhibitor 1
  • HY-114168
    KRAS G12C inhibitor 5
    		Inhibitor
    KRAS G12C inhibitor 5 is a KRas G12C inhibitor extracted from patent WO2017201161A1, Compound example 147.
    KRAS G12C inhibitor 5
Cat. No. Product Name / Synonyms Application Reactivity
Ras Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.